Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AZN: AstraZeneca PLC -- Ignore unavailable to you. Want to Upgrade?

To: Ausdauer who wrote (14)	7/22/2002 2:02:14 PM
From: EdR	Respond to of 35

Aus, Looked to me like "Creditors due within 1 yr." of 788Mil, was Accounts Payable... Ed...

To: Ausdauer who wrote (14)	7/25/2002 1:11:36 PM
From: EdR	Read Replies (1) \| Respond to of 35

These numbers look good to me unless there's stuff going on that we can't see... From the DJ News Service: AstraZeneca Posts 4.5% Profit Rise in 2nd Quarter Dow Jones Newswires LONDON -- AstraZeneca (NYSE: AZN - News) PLC Thursday said second-quarter pretax profit rose 4.5% to $1.07 billion from $1.02 billion a year earlier. Pretax profit for the six months to June 30 was 12% higher at $2.38 billion, compared with $2.13 billion, the company said. Sales totaled $8.8 billion, up 8.8% from $8.09 billion. "A strong performance from the launch rollouts of Nexium and Symbicort, together with continued growth from Seroquel, Atacand, and our range of cancer medicines has delivered a good set of results in the first half," said Tom McKillop, AstraZeneca 's chief executive. "The business remains on track to meet its financial targets for the full year," he said. Sales for the second quarter rose 6.9% to $4.38 billion from $4.1 billion a year earlier, and operating profit rose 6.8% to $1.06 billion from $996 million, the company said. AstraZeneca said Nexium achieved sales of $830 million for the first half; sales in the last 12 months reached $1.3 billion. Symbicort sales were $122 million in the latest half. Mutual Recognition Procedure in European Union for the use of Symbicort as a maintenance treatment for asthma in children age 6-11 years was successfully completed on July 5 , the company said. Cash generated from operating activities amounted to $3.1 billion for the first half with lower working capital contributing $300 million, the company said. This was applied to capital expenditures of $600 million, taxation paid of $400 million, dividends of $800 million and share repurchases of $700 million to give an increase in net cash funds of $600 million. The company declared an interim dividend of 23 cents per share.